Jump to ContentJump to Main Navigation

Serbian Journal of Dermatology and Venereology

The Journal of Serbian Association of Dermatovenereologists (SAD)

4 Issues per year

Open Access

Open Access

Myofibroblastic Dermatofibroma: An Unusual Variant / Miofibroblastni Dermatofibrom: Neuobičajena Varijacija

Cynthia Okoduwa1 / Robyn D. Siperstein1 / Wen Chen1 / Rajit Malliah1 / Valerie Fitzhugh1 / W. Clark Lambert1 / 1

1Dermatology and Pathology, New Jersey Medical School, 185 South Orange Avenue, Newark, New Jersey 07103

This content is open access.

Citation Information: Serbian Journal of Dermatology and Venerology. Volume 1, Issue 1, Pages 34–37, ISSN (Print) 1821-0902, DOI: 10.2478/v10249-011-0099-4, February 2013

Publication History

Published Online:


Myofibroblastic dermatofibroma (MFD) is an unusual neoplasm characterized by a predominance of myofibroblastic differentiation. It is extremely rare and it is not well described. Expressions of smooth muscle actin, CD34, S-100, desmin, CD31, and Factor XIIIa were evaluated along with hematoxylin-eosin and trichrome staining of fixed tissue specimens from a fibrohistiocytic neoplasm. The neoplasm demonstrated a storiform pattern characteristic of fibrohistiocytic origin. It was strongly and diffusely positive for smooth muscle actin and vimentin, and negative for all other stains performed. A trichrome stain showed the entire tumor to be blue, demonstrating the collagenous and fibrous tissue to a marked degree. MFD is a distinct variant of dermatofibroma characterized by a predominance of myofibroblastic differentiation.


Uvod: Miofbroblastni dermatofbrom (MFD) neobičan je tumor karakterističan po tome što kod njega preovladava miofbroblastna diferencijacija. Veoma je redak i nedovoljno opisan u literaturi.

Metode: Ispitivanje je obuhvatilo ekspresiju aktina glatkih mišića, CD34, S-100, dezmin, CD31 i faktor XIIIa, kao i histopatološke analize hematoksilin-eozin i trihromnim bojenjem fksiranih uzoraka tkiva fbro-histiocitnih tumora.

Rezultati: Histopatološki, tumor se sastojao od vretenastih ćelija, karakterističnih za fbrohistiocitno poreklo. Imunohemijskom analizom dobijena je pozi-tivna reakcija na aktin i vimentin glatkih mišića, dok je na ostala bojenja reakcija bila negativna. Trihrom-nim bojenjem dobijena je potpuna obojenost tumora plavom bojom, što je do određene granice demonstri-ralo i kolagenozno i fbrozno tkivo.

Zaključak: MFD je posebna varijanta dermatofbroma sa karakterističnim prisustvom miofbroblastne diferen-cijacije.

  • 1. Zelger BG, Zelger BWH. Myofibroblastic dermatofibroma: a cutaneous variant of intranodal myofibroblastoma. Am J Dermatopathol 1996;18:441.

  • 2. Zelger B, Zelger G, Burgdorf WHC. Dermatofibroma: a critical evaluation. Int J Surg Pathol 2004;12:333-44. [PubMed] [CrossRef]

  • 3. Eyden B. Fibroblast phenotype plasticity: relevance for understanding heterogenity in „fibroblastic“ tumors. Ultrastruct Pathol 2004;28:307-19. [CrossRef]

  • 4. Fisher C. Myofibroblastic malignancies. Adv Anat Pathol 2004;11:190-201. [PubMed] [CrossRef]

  • 5. Zelger BG, Sidoroff A, Zelger B. Combined dermatofibroma: co-existence of two or more variant patterns in a single lesion. Histopathology 2000;36:529-39. [CrossRef]

  • 6. Eyden B. The myofibroblast: a study of normal, reactive and neoplastic tissues, with an emphasis on ultrastructure. part 2 - tumours and tumour-like lesions. J Submicrosc Cytol Pathol 2005;37:231-96.

  • 7. Fletcher CD. Myofibroblastic tumours: an update. Verh Deutsc Ges Pathol 1998;82:75-82.

  • 8. Calonje E. Is cutaneous benign fibrous histiocytoma (dermatofibroma) a reactive inflammatory process or neoplasm? Histopathology 2000;37:278-80. [CrossRef] [PubMed]

  • 9. Eyden B. Electron microscopy in the study of myofibroblastic lesions. Semin Diagn Pathol 2003;20:13-24.

  • 10. Zelger BG, Zelger B. Dermatofibroma (fibrous histiocytoma): An inflammatory or neoplastic disorder? Histopathology 2001;38:379-81. [PubMed] [CrossRef]

  • 11. Zelger BW, Zelger BG, Rappersberger K. Prominent myofibroblastic differentiation: a pitfall in the diagnosis of dermatofibroma. Am J Dermatopathol 1997;19:138-46.

  • 12. Eyden BP, Harris M, Greywoode GJ, Christensen L, Banerjee SS. Intranodal myofibroblastoma: report of a case. Ultrastrucl Pathol 1996;20:79-88. [CrossRef]

  • 13. Eyden BP, Ponting J, Defining the myofibroblast: normal tissues, with special reference to the stromal cells of Wharton’s jelly in human umbilical cord. J Submicrosc Cytol Pathol 1994;26:347-55.

  • 14. Dishop MK, Warner BW, Dehner LP, et al. Successful treatment of inflammatory myofibroblastic tumor with malignanttransformation by surgical resection and chemotherapy. J Pediatr Hematol Oncol 2003;25:153-8. [CrossRef]

Comments (0)

Please log in or register to comment.